Perjeta 420 MG/14 ML vial 14ML
Ended Awarded Last action
- Contract number
- SPE2DR26FMEC3
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $41,859
Award facts
- Contract value 100% obligated
- $41,858.82 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $41,858.82 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Perjeta 420 mg/14 mL vials. The delivery order, issued on December 16, 2025, with an ultimate completion date of January 8, 2026, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This award represents a single delivery order issued under DMS Pharmaceutical Group's broader Indefinite Delivery Contract with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to provide comprehensive pharmaceutical supply support to Department of Defense military healthcare facilities worldwide.
DMS Pharmaceutical Group Inc. has established itself as a critical supplier within the federal pharmaceutical supply chain, leveraging its small business status and extensive product portfolio spanning oncology treatments, biologics, vaccines, and specialty pharmaceuticals to meet recurring medical supply needs across the military healthcare system. The company's single-award IDC under PPV-G GEN V, valued at $499.999 billion with a completion date of December 31, 2036, positions it as a regional prime vendor contractor capable of fulfilling diverse and specialized pharmaceutical requirements across multiple therapeutic categories. The delivery order award reflects DMS Pharmaceutical Group's consistent contract performance and its role as a key distributor supporting Department of Defense operations.
Quick answers
Who was awarded contract SPE2DR26FMEC3?
SPE2DR26FMEC3 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 16, 2025.
How much is contract SPE2DR26FMEC3 worth?
The government has obligated $41,859 on SPE2DR26FMEC3.
Is contract SPE2DR26FMEC3 an order under another contract?
Yes. SPE2DR26FMEC3 is a delivery order under SPE2DR25D9114, an indefinite delivery contract.
Was contract SPE2DR26FMEC3 competed?
The extent of competition for SPE2DR26FMEC3 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award